DTIL News and Press, Precision BioSciences Inc.

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, is presenting data today at the United Mit...

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced the appointment of Mark Su...

- PBGENE-HBV specifically cuts HBV DNA without impacting the human genome - PBGENE-HBV was well tolerated across multiple administrations with no off-target editing observed - Preclinical safety data supports advancement of PBGENE-HBV to clinical trials as a potentially curative...

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that members of management...

2024-05-26 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-16 15:15:03 ET H.C. Wainwright analyst issues BUY recommendation for DTIL on May 16, 2024 02:00PM ET. The previous analyst recommendation was Buy. DTIL was trading at $12.0201 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curren...

2024-05-13 07:21:43 ET More on Precision BioSciences Precision BioSciences Q1 Earnings Preview Eli Lilly subsidiary, Precision Biosciences end gene therapy collaboration Seeking Alpha’s Quant Rating on Precision BioSciences Historical earnings data for...

Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...

- Wholly owned programs on track for CTA and/or IND submissions - PBGENE-HBV for Hepatitis B virus in 2024 and PBGENE-PMM for primary mitochondrial myopathy in 2025 - First ARCUS in vivo gene editing program now open for enrollment in the United Kingdom through partnered OTC deficiency ...

2024-05-10 12:45:24 ET More on Precision BioSciences Eli Lilly subsidiary, Precision Biosciences end gene therapy collaboration Precision BioSciences stock falls after pricing $40M securities offering Seeking Alpha’s Quant Rating on Precision BioSciences ...